Exelixis Inc (EXEL) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsHold27 analystsWhat's happening with EXEL
Price History
5-Year Weekly Candlestick Chart
Profile
Strong profitability, financial health and growth.
How is each axis scored?
- Valuation62/100 · Moderate
- P/E vs own history (34th pct)20/25
- FCF yield (6.4%)20/25
- P/S (6.1x)12/25
- EV/EBIT (n/a)10/25
- Growth82/100 · Strong
- Revenue CAGR (12.8%)20/25
- Net income CAGR (35.7%)25/25
- EPS CAGR 5Y (40.3%)25/25
- Fwd implied growth (14.9%)12/25
- Profitability100/100 · Strong
- ROIC (63.9%)25/25
- ROE (43.1%)25/25
- Net margin (35.1%)25/25
- Operating margin (39.4%)25/25
- Financial Health100/100 · Strong
- Altman Z (15.00)25/25
- Current ratio (3.26)25/25
- Interest coverage (42.7x)25/25
- Net cash / debt (Net cash)25/25
- Quality65/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-2.64)25/25
- FCF conversion (110%)25/25
- Margin stability (σ 61.5%)0/25
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Show more
Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Headquarters: ALAMEDA, CA · Employees: 1,077 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-08-12-9812 sh2026-08-10
- SellOpen market sale · filed 2026-06-03-9812 sh2026-06-01
- SellOpen market sale · filed 2026-06-03-3925 sh2026-06-01
- BuyGrant / award · filed 2026-05-29+8.4K sh2026-05-27
- BuyGrant / award · filed 2026-05-29+8.4K sh2026-05-27
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
62BP/E (TTM)18.7xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 14.0x–85.0x · 34th pct
P/FCF12.5xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.4%A
Grade A: ValueTTM FCF / Market Cap — vs own 5Y history: 3.2%–8.3% · 73rd pct
P/S (TTM)6.07xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.0x–6.7x · 96th pct
EV/EBITDA14.3xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales5.9xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E16.2xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio7.44xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.19B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC63.9%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE43.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA32.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin35.1%A
Grade A: HighNet Income / Revenue
Operating Margin39.4%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin96.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin38.6%A
Grade A: HighFCF / Revenue
True FCF Margin33.7%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
100A+Altman Z-Score15.00A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.26xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.32xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage42.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
82ARevenue CAGR12.8%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR35.7%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)40.3%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth14.9%B
Grade B: LowImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-16.8%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income13.9%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.9%C
Grade C: MedTTM stock-based comp / TTM Revenue
Quality
1/10 Loss Years65BPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.64A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion110.1%A
Grade A: StrongFCF / Net Income
Margin Stability61.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.3%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.82xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$3.12
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.03
Cash & short-term investments per share (Finnhub)
Book Value / Share$8.23
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$777.21M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$1.94B
Shareholders' equity (book value)
Asset / Liability3.94xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$14.41B
Current Market Capitalization
Beta0.49B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Neutral
Company is effectively debt-free after netting cash. · Current P/E of 18.7x sits at the 34th percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Apr 2026 · Ratio snapshot Sep 23, 2026
Key Insights: Exelixis Inc (EXEL)
Composite verdict for Exelixis Inc: Neutral. Piotroski F-Score of 6/9 indicates mixed fundamentals for Exelixis Inc. Altman Z-Score of 15.00 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.64 suggests a low likelihood of earnings manipulation.
- Exelixis Inc converts about 39% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Exelixis Inc posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- Return on equity of 43.1% is well above the market average.
See how EXEL ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for EXEL in the last 30 days.
See EXEL move history →Frequently Asked Questions about EXEL
Is EXEL stock a buy right now?
PreMarketPrice's quantitative model rates Exelixis Inc's financial health at 100/100 — Neutral. This is a data-driven snapshot of fundamentals, not investment advice.
Is EXEL stock overvalued?
Exelixis Inc trades at a trailing P/E of 18.7 and our valuation score rates it 62/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Exelixis Inc report earnings?
No confirmed earnings date is currently scheduled for EXEL. The Earnings section lists recent reports and updates as dates are announced.
What sector does Exelixis Inc operate in?
Exelixis Inc operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Exelixis Inc do?
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer.
About Exelixis Inc (EXEL) Stock
Exelixis Inc (EXEL) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. Real-time pricing data for Exelixis Inc is available on this page with a market capitalization of $14.4 billion. The financial health score for EXEL is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for EXEL stock.
EXEL Stock Analysis & Key Metrics
On PreMarketPrice, you can track Exelixis Inc (EXEL) across multiple dimensions:
- Pre-market price & movement: Real-time EXEL stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for EXEL with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Exelixis Inc across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for EXEL.
- Sector peers: Compare EXEL against 10 other healthcare stocks on key financial metrics.
Is EXEL a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Exelixis Inc (EXEL) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Exelixis Inc (EXEL) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.